ApoA1 Antibody [L13J2]

Catalog No.: F5020

Application: Reactivity: Human

Lane 1: Human small intestine, Lane 2: Human plasma

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000

Application
WB

Source
Mouse Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
25 kDa

Datasheet & SDS

生物学的記述

Specificity
ApoA1 Antibody [L13J2] detects endogenous levels of total ApoA1 protein.

Clone
L13J2

Synonym(s)
Apolipoprotein A-I; Apo-AI; ApoA-I; Apolipoprotein A1; APOA1

Background
Apolipoprotein A-I (ApoA-I) is the primary structural and functional protein of high-density lipoprotein (HDL), synthesized mainly in the liver and intestine to mediate reverse cholesterol transport by facilitating ABCA1-dependent cholesterol efflux from peripheral tissues to the liver for excretion, thereby offering protection against atherosclerosis and cardiovascular disease. The mature 243-amino-acid ApoA-I polypeptide comprises 10 tandem repeats of amphipathic α-helices, with proline residues providing flexibility for lipid binding; its N-terminal region stabilizes the lipid-free form, the central domain (140–170) activates lecithin-cholesterol acyltransferase (LCAT) for cholesterol esterification and HDL maturation, and the C-terminal domain (181–243) enables high-affinity phospholipid binding for nascent HDL formation. ApoA-I serves as a cofactor for LCAT, interacts with ABCA1 and SR-BI receptors to promote lipid efflux, and exhibits strong anti-inflammatory and antioxidant actions by neutralizing lipopolysaccharides and inhibiting vascular adhesion molecule expression. Low ApoA-I levels are an independent risk predictor for coronary artery disease, while APOA1 mutations cause familial HDL deficiency syndromes or hereditary amyloidosis, leading to accelerated atherosclerosis or organ dysfunction from protein deposits, with additional links to Alzheimer’s disease and diabetes through impaired lipid homeostasis and chronic inflammation.

Background

Apolipoprotein A-I (ApoA-I) is the primary structural and functional protein of high-density lipoprotein (HDL), synthesized mainly in the liver and intestine to mediate reverse cholesterol transport by facilitating ABCA1-dependent cholesterol efflux from peripheral tissues to the liver for excretion, thereby offering protection against atherosclerosis and cardiovascular disease. The mature 243-amino-acid ApoA-I polypeptide comprises 10 tandem repeats of amphipathic α-helices, with proline residues providing flexibility for lipid binding; its N-terminal region stabilizes the lipid-free form, the central domain (140–170) activates lecithin-cholesterol acyltransferase (LCAT) for cholesterol esterification and HDL maturation, and the C-terminal domain (181–243) enables high-affinity phospholipid binding for nascent HDL formation. ApoA-I serves as a cofactor for LCAT, interacts with ABCA1 and SR-BI receptors to promote lipid efflux, and exhibits strong anti-inflammatory and antioxidant actions by neutralizing lipopolysaccharides and inhibiting vascular adhesion molecule expression. Low ApoA-I levels are an independent risk predictor for coronary artery disease, while APOA1 mutations cause familial HDL deficiency syndromes or hereditary amyloidosis, leading to accelerated atherosclerosis or organ dysfunction from protein deposits, with additional links to Alzheimer’s disease and diabetes through impaired lipid homeostasis and chronic inflammation.

References
[1] Frank PG, et al. J Lipid Res. 2000 Jun;41(6):853-72. [2] Mangaraj M, et al. Indian J Clin Biochem. 2016 Jul;31(3):253-9.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%